financetom
Business
financetom
/
Business
/
Cadence Design Systems Faces Mounting Risks in Long Term, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cadence Design Systems Faces Mounting Risks in Long Term, Oppenheimer Says
Mar 19, 2025 9:45 AM

12:07 PM EDT, 03/19/2025 (MT Newswires) -- Cadence Design Systems ( CDNS ) faces mounting long-term risks, including limited cloud adoption, reliance on on-premise licensing and the industry's shift to consumption-based models, Oppenheimer said Wednesday in a report.

Artificial intelligence presents a dual challenge for Cadance, acting as both a potential disruptor and enhancer of its offerings with emerging AI-native tools, particularly from China, posing competitive threats, Oppenheimer said.

Despite a partial stock rebound, Cadence continues to struggle following disappointing 2025 guidance, the report said. Revenue growth has slowed for three straight years, dropping to an estimated 12% in 2025 from 19% in 2022, Oppenheimer said.

Oppenheimer lowered its price target on Cadence stock to $200 from $225 and maintained its underperform rating, underscoring concerns about the company's ability to adapt to structural shifts in the market.

Cadence shares rose 3.2% in recent trading Wednesday.

Price: 261.87, Change: +7.99, Percent Change: +3.15

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
scPharmaceuticals Secures FDA Approval of New Drug Application to Expand Furoscix Indication
scPharmaceuticals Secures FDA Approval of New Drug Application to Expand Furoscix Indication
Aug 12, 2024
07:55 AM EDT, 08/12/2024 (MT Newswires) -- scPharmaceuticals (SCPH) said Monday the US Food and Drug Administration has approved the company's supplemental new drug application to expand the Furoscix indication for heart failure patients. Furoscix was previously only indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association Class I and Class...
Arcosa Plans to Launch $600 Million Private Offering of Senior Notes
Arcosa Plans to Launch $600 Million Private Offering of Senior Notes
Aug 12, 2024
07:56 AM EDT, 08/12/2024 (MT Newswires) -- Arcosa ( ACA ) said Monday it plans to launch a private offering of $600 million of senior unsecured notes due 2032. The company said it plans to use the net proceeds, together with expected borrowings under its term loan B facility due 2031, to fund the $1.2 billion acquisition of Stavola Holding's...
Geodrill's Q2 Net Income More Than Doubles on Record Revenue
Geodrill's Q2 Net Income More Than Doubles on Record Revenue
Aug 12, 2024
07:56 AM EDT, 08/12/2024 (MT Newswires) -- Geodrill ( GEODF ) said Monday that its net income more than doubled in the second quarter as it booked record revenue during the period. The West African based drilling company posted a net income of US$4.8 million, or US$0.10 per share, surging from US$2.0 million, or US$0.04 per share. Revenue jumped 26%...
Synopsys' $35 billion Ansys deal under UK regulator scrutiny
Synopsys' $35 billion Ansys deal under UK regulator scrutiny
Aug 12, 2024
(Reuters) - UK's competition watchdog said on Monday it was looking into whether chip design software maker Synopsys' ( SNPS ) $35 billion acquisition of Ansys ( ANSS ) would affect competition in Britain. The Competition and Markets Authority (CMA) is yet to launch a formal investigation into the deal. CONTEXT In January, chip design software maker Synopsys ( SNPS...
Copyright 2023-2026 - www.financetom.com All Rights Reserved